Non-Hodgkin's Lymphoma Is a Group of Blood Cancers That Start in Lymph Cells

Non-Hodgkin's lymphoma (NHL) is cancer that begins in the lymphocytes—white blood cells that fight infection—found in your lymph nodes, bone marrow, spleen, and other lymphoid tissues. Unlike Hodgkin's lymphoma, which spreads in an orderly way from one lymph node group to the next, NHL can appear in multiple, scattered locations at once. This difference in how the cancer spreads is the main distinction between the two types.

NHL is actually not one disease but a collection of more than 60 different subtypes, each with different growth rates, locations, and responses to treatment. Some grow slowly (indolent), while others grow quickly (aggressive). Some start in B cells, others in T cells, and a few in natural killer cells. This variety means two people diagnosed with NHL may have very different experiences and treatment paths.

The disease occurs when lymphocytes begin to divide uncontrollably and accumulate in lymph nodes or other organs. Over time, these abnormal cells crowd out healthy cells and interfere with immune function. NHL can develop at any age but becomes more common as people get older, with most cases occurring in people over 60.

Key Takeaways

  • Non-Hodgkin's lymphoma is cancer of lymphocytes that can appear in multiple body locations at once, unlike Hodgkin's lymphoma which spreads in an orderly pattern.
  • There are more than 60 subtypes of NHL, classified by cell type (B cell, T cell, or natural killer cell) and growth rate (slow or fast), which affects treatment options.
  • Symptoms include swollen lymph nodes, fever, night sweats, and weight loss, though some people have no symptoms and are diagnosed during tests for other reasons.
  • Diagnosis requires a biopsy of affected tissue to identify the specific subtype, which determines the stage of disease and guides treatment decisions.

How NHL Develops and Why It Matters Which Subtype You Have

NHL begins when a single lymphocyte develops a genetic mutation that causes it to divide repeatedly without the normal signals to stop. This mutated cell multiplies into millions of identical copies—a clone—that accumulate in lymph nodes, bone marrow, spleen, or other organs. The specific gene involved in the mutation determines which subtype of NHL develops.

The subtype matters because it predicts how fast the cancer will grow and how it will respond to treatment. Indolent (slow-growing) subtypes like follicular lymphoma may remain stable for years without treatment, but they are typically harder to cure. Aggressive (fast-growing) subtypes like diffuse large B-cell lymphoma grow quickly but often respond well to intensive chemotherapy. Some subtypes are associated with specific infections or conditions—for example, certain T-cell lymphomas are linked to human T-cell leukemia virus (HTLV-1).

Doctors identify the subtype through a biopsy, which involves removing a small sample of tissue from an affected lymph node or organ and examining it under a microscope. The pathologist looks at the cell type, growth pattern, and genetic markers to determine which of the 60+ subtypes is present. This information is essential because treatment plans differ significantly between subtypes.

Common Symptoms and How They Develop

Many people with NHL first notice swollen lymph nodes in the neck, armpit, or groin that don't go away after a few weeks. These nodes may be painless or tender. Some people experience systemic symptoms—fever, night sweats that soak through clothing, and unintended weight loss—that occur because the cancer cells release substances that affect the whole body.

Other symptoms depend on where the cancer is located. If NHL involves the chest, a person may have a persistent cough or shortness of breath. If it affects the abdomen, there may be abdominal pain or swelling. If it involves the bone marrow, it can cause fatigue and easy bruising because the cancer crowds out healthy blood cells. Some people have no symptoms at all and are diagnosed when imaging or blood work done for another reason reveals abnormal lymph nodes.

These symptoms can also result from infections or other conditions. A doctor needs to evaluate them in context and may order imaging or blood tests to determine the cause. Symptoms alone do not confirm NHL; a biopsy is required for diagnosis.

Staging: How Doctors Determine How Far the Cancer Has Spread

Once NHL is diagnosed, doctors perform staging tests to determine how many lymph node groups are involved and whether the cancer has spread to organs like the liver, spleen, or bone marrow. Staging uses the Roman numerals I through IV, with stage I meaning cancer is in one lymph node group and stage IV meaning it has spread to organs outside the lymph system.

Staging tests typically include a CT scan of the chest, abdomen, and pelvis to visualize lymph nodes and organs, and a bone marrow biopsy to check whether cancer cells are present there. Some subtypes also require a PET scan, which uses a radioactive tracer to show which areas have high cell activity. Blood tests measure levels of certain proteins and cell counts that provide additional information about disease burden.

Stage is one factor in prognosis, but subtype and other factors matter too. A person with stage IV indolent lymphoma may have a different outlook than someone with stage II aggressive lymphoma. Doctors use staging information along with subtype, age, and other factors to estimate prognosis and recommend treatment.

Risk Factors: Who Develops Non-Hodgkin's Lymphoma

Age is the strongest risk factor—NHL becomes significantly more common after age 60. Men are diagnosed more often than women. People with weakened immune systems, whether from HIV infection, organ transplant, or immunosuppressive medications, have higher risk. Certain infections increase risk: hepatitis C virus, human T-cell leukemia virus (HTLV-1), and Epstein-Barr virus are all associated with specific NHL subtypes.

Autoimmune diseases like rheumatoid arthritis and celiac disease carry modestly increased risk. Exposure to certain chemicals, particularly pesticides and herbicides, has been studied as a potential risk factor, though the evidence remains incomplete. Some people have a family history of lymphoma, suggesting genetic factors play a role, though most NHL cases occur in people without a family history.

Having a risk factor does not mean a person will develop NHL. Most people with risk factors never develop the disease. Conversely, many people diagnosed with NHL have no known risk factors.

How NHL Differs From Hodgkin's Lymphoma

The key difference is how the cancer spreads. Hodgkin's lymphoma typically spreads in an orderly, predictable way from one lymph node group to adjacent groups. Non-Hodgkin's lymphoma can skip lymph node groups and appear in multiple, distant locations simultaneously. This difference affects staging and treatment planning.

NHL is also more common than Hodgkin's lymphoma—about 90% of all lymphoma cases are NHL. NHL occurs across a much wider age range, though both types become more common with age. The subtypes are also different: Hodgkin's lymphoma has only a few subtypes, while NHL has more than 60. Treatment approaches differ as well, though both may use chemotherapy, radiation, or targeted therapies depending on the specific disease.

Prognosis varies widely for both types. Some people with indolent NHL live for many years with the disease, while others with aggressive subtypes may achieve remission with intensive treatment. Hodgkin's lymphoma generally has better overall survival rates, particularly in younger people, but individual outcomes depend on many factors.

What Happens After Diagnosis: Next Steps in Understanding Your Situation

After a biopsy confirms NHL and staging tests are complete, your doctor will discuss the specific subtype, stage, and other prognostic factors with you. This information forms the basis for treatment recommendations. For some indolent subtypes, the recommendation may be "watch and wait"—monitoring the disease without immediate treatment if it is not causing symptoms or organ damage.

For other subtypes, treatment typically begins soon after diagnosis. Options may include chemotherapy, targeted therapies that attack specific proteins on cancer cells, monoclonal antibodies that help the immune system recognize cancer cells, or radiation therapy. Some people receive a combination of these. The goal of treatment varies: for aggressive subtypes, the goal is usually remission; for indolent subtypes, the goal may be to control the disease long-term.

Your doctor will also discuss potential side effects of treatment, follow-up monitoring plans, and what to expect during and after treatment. This is a good time to ask questions about your specific subtype, what the treatment plan is designed to achieve, and what the realistic outlook is based on current evidence.

Frequently Asked Questions

Is Non-Hodgkin's lymphoma the same as cancer?

Yes, Non-Hodgkin's lymphoma is a type of cancer. It is cancer of lymphocytes, the white blood cells that normally fight infection. Like other cancers, it involves cells that divide uncontrollably and can spread to other parts of the body if not treated.

Can you survive Non-Hodgkin's lymphoma?

Survival depends on many factors, including the specific subtype, stage at diagnosis, age, and overall health. Some subtypes have high cure rates, particularly when diagnosed early and treated aggressively. Others are managed as chronic diseases, with people living for many years. Your doctor can discuss the outlook for your specific situation based on your subtype and stage.

What is the difference between B-cell and T-cell lymphoma?

B-cell and T-cell lymphomas are named for the type of lymphocyte involved. B-cell lymphomas are more common, accounting for about 85% of NHL cases. T-cell lymphomas are less common but can behave differently and may require different treatment approaches. The distinction is made during biopsy and pathology examination.

Does Non-Hodgkin's lymphoma run in families?

Most NHL cases are not inherited. However, people with a family history of lymphoma may have a slightly higher risk. Genetic factors likely play a role, but most people with NHL have no family history of the disease, and most people with a family history never develop it.

Can Non-Hodgkin's lymphoma come back after treatment?

Relapse is possible with some subtypes, particularly indolent lymphomas that may recur years after initial treatment. Aggressive subtypes that go into remission may also relapse, though some people remain in remission long-term. Your doctor will discuss the risk of relapse for your specific subtype and the monitoring plan after treatment ends.